Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,101–4,200 of 10,906
Nicastro, E., Ebel, N. H., Kehar, M., Czubkowski, P., Ng, V. L., Michaels, M. G., Lobritto, S., Martinez, M., & Indolfi, G. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003339 · Cited by 16
Zhang, S., Chen, S., Xiao, G., Zhao, M., Li, J., Dong, W., Hu, J., Yuan, T., Li, Y., & Liu, L. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16786-y · Cited by 16
Edwards, K. R., Malhi, H., Schmidt, K., Davis, A. R., Homad, L. J., Warner, N. L., Chhan, C. B., Scharffenberger, S. C., Gaffney, K., Hinkley, T. C., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00907-y · Cited by 17
Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases
Wang, X., Gao, X., Wang, L., Lin, J., & Liu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202305061 · Cited by 19
Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity
Asamoah-Boaheng, M., Goldfarb, D. A., Prusinkiewicz, M. A., Golding, L., Karim, M. E., Barakauskas, V., Wall, N., Jassem, A. N., Marquez, A. C., MacDonald, C., et al. (2023) · Cureus · doi:10.7759/cureus.34465 · Cited by 16
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
Benucci, M., Damiani, A., Gobbi, F. L., Lari, B., Grossi, V., Infantino, M. G., & Manfredi, M. (2022) · Immunologic Research · doi:10.1007/s12026-022-09283-y · Cited by 17
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccinePreprint
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A.-Y., Grunenberg, N., Allen, M., Antony, J., Asante, K., Bhate, A., Beresnev, T. H., et al. (2022) · medRxiv · doi:10.1101/2022.12.05.22282933 · Cited by 13
Self-citationDelayed allergic skin reactions to vaccines
Aquino, M., Bingemann, T. A., Nanda, A., & Maples, K. M. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.210105 · Cited by 16
Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias
Álvarez, F. V., Martínez‐García, M. Á., Jiménez, D. G., Fariñas-Guerrero, F., de Lejarazu-Leonardo, R. O., López-Campos, J. L., Blanco‐Aparicio, M., Royo-Crespo, Í., García‐Ortega, A., García, A. T., et al. (2021) · Open Respiratory Archives · doi:10.1016/j.opresp.2021.100097 · Cited by 17
Bozkurt, B., Das, S. R., Addison, D., Gupta, A., Jneid, H. M., Khan, S. S., Koromia, G. A., Kulkarni, P. A., LaPoint, K., Lewis, E. F., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.355 · Cited by 19
ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
Maguire, D., McLaren, D. S., Rasool, I., Shah, P. M., Lynch, J. M., & Murray, R. D. (2021) · Clinical Endocrinology · doi:10.1111/cen.14566 · Cited by 16
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Muthukutty, P., MacDonald, J., & Yoo, S. Y. (2024) · Vaccines · doi:10.3390/vaccines12111220 · Cited by 20
Yi, S. G., Moore, L. W., Eagar, T. N., Graviss, E. A., Nguyen, D. T., Ibrahim, H. N., Huang, H. J., Hobeika, M. J., McMillan, R. R., Saharia, A., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001257 · Cited by 15
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 18
Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15
Self-citationRisk of COVID-19 after natural infection or vaccination
Rick, A.-M., Laurens, M. B., Huang, Y., Yu, C., Martin, T., Rodriguez, C. A., Rostad, C. A., Maboa, R., Baden, L. R., Sahly, H. M. E., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104799 · Cited by 22
Self-citationZheng, M., Zhong, W., Chen, X., Wang, N., Liu, Y., Zhang, Q., Cheng, Y., Li, W., Yu, Q., Zhao, X., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2090776 · Cited by 18
Nanotechnology-based approaches in the fight against SARS-CoV-2
Albaz, A. A., Rafeeq, M. M., Sain, Z. M., Almutairi, W. A., Alamri, A. S., Aloufi, A. H., Almalki, W. H., & Tarique, M. (2021) · AIMS Microbiology · doi:10.3934/microbiol.2021023 · Cited by 16
SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
Purushotham, J. N., van Doremalen, N., & Munster, V. J. (2021) · Cell Research · doi:10.1038/s41422-021-00516-7 · Cited by 14
Monkeypox: A comprehensive review on mutation, transmission, pathophysiology, and therapeutics
Dutta, S., Ghosh, R., Dasgupta, I., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113813 · Cited by 15
Lei, H., Hong, W., Yang, J., He, C., Zhou, Y., Zhang, Y., Alu, A., Shi, J., Liu, J., qin, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02025-6 · Cited by 20
A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy
Antonini, C., Calandrini, S., & Bianconi, F. (2021) · Vaccines · doi:10.3390/vaccines9080915 · Cited by 15
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma
Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J. F., Rai, D., Korecka, J. A., Khurana, V., Murugaiyan, G., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf162 · Cited by 22
“52,53 Given miR-10b’s unique properties as a target, miRTEN could advance as one of the first in vivo GE therapies for malignant gliomas.”
COVID-19 vaccines: Frequently asked questions and updated answers
Lefebvre, M., Vignier, N., Pitard, B., Botelho-Nevers, É., Wyplosz, B., Cohen, R., & Épaulard, O. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.02.007 · Cited by 17
Nanocarriers for inhaled delivery of RNA therapeutics
Huayamares, S. G., Zenhausern, R., & Loughrey, D. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100200 · Cited by 17
Singh, R., Li, J., Parmar, U., Jeng, B., & Jhanji, V. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-322512 · Cited by 13
Jeyanthi, V., Govindarajan, V. K., Sekaran, S., & Venkatapathy, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.637378 · Cited by 15
Retrospective study on the safety of COVID ‐19 vaccination in myasthenia gravis
Pincheira, A. U., Alnajjar, S., Katzberg, H. D., Barnett, C., Daniyal, L., Rohan, R., & Bril, V. (2022) · Muscle & Nerve · doi:10.1002/mus.27657 · Cited by 15
Shahrear, S., & Islam, A. B. M. M. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105098 · Cited by 17
COVID-19 vaccines: Update of the vaccines in use and under development
Marta, R. A., Nakamura, G. E. K., Aquino, B. D. M., & Bignardi, P. R. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacun.2022.06.003 · Cited by 17
Novel coronavirus mutations: Vaccine development and challenges
Luo, W.-R., Wu, X., Wang, W., Yu, J., Chen, Q., Zhou, X., Huang, X., Pan, H., Liu, Z., Gao, Y., et al. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105828 · Cited by 19
Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Komiya, E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.018 · Cited by 15
Méndez-García, A., García-Mendoza, M. A., Zárate-Peralta, C. P., Flores-Pérez, F. V., Carmona-Ramirez, L. F., Pathak, S., Banerjee, A., Duttaroy, A. K., & Paul, S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1555563 · Cited by 22
Protocol of safe vaccination against COVID‐19 in patients with high risk of allergic reactions
Romantowski, J., Kruszewski, J., Solarski, O., Bant, A., Chciałowski, A., Pietrzyk, I., Sańpruch, P., Górska, A., Chełmińska, M., Knurowska, A., et al. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12152 · Cited by 14
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 19
Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection
Rahman, M. S., Han, M. J., Kim, S. W., Kang, S. M., Kim, B. R., Kim, H., Lee, C. J., Noh, J. E., Kim, H., Lee, J., et al. (2023) · Molecules · doi:10.3390/molecules28124645 · Cited by 18
Current clinical status of new COVID-19 vaccines and immunotherapy
Nagpal, D., Nagpal, S., Kaushik, D. K., & Kathuria, H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22661-1 · Cited by 19
Rai, C.-I., Kuo, T.-H., & Chen, Y. (2024) · Vaccines · doi:10.3390/vaccines12091002 · Cited by 22
Tang, L., Zhang, Y., Wang, F., Wu, D., Qian, Z., Zhang, R., Wang, A., Huang, C., Wang, H., Ye, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063919 · Cited by 17
Egberink, R. O., Zegelaar, H. M., Boujnouni, N. E., Versteeg, E. M. M., Daamen, W. F., & Brock, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081619 · Cited by 16
Mucosal vaccines for viral diseases: Status and prospects
Ma, B., Tao, M., Li, Z., Zheng, Q., Haigang, W., & Chen, P. (2024) · Virology · doi:10.1016/j.virol.2024.110026 · Cited by 17
Tebas, P., Patel, A. R., Agnes, J. T., Parzych, E. M., Baer, A. L., Caturla, M., Ghosh, S., Purwar, M., Bedanova, N. M., Tsang, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03969-0 · Cited by 18
“Detailed characterization is provided in Supplementary Tables 2 and 4, while Supplementary Tables 6 and 7 summarize the number of participants who experienced at least one local or systemic elicited reaction within 7 or 10 days after dosing.”
InfluentialLipid nanoparticles-based RNA therapies for breast cancer treatment
Serpico, L., Zhu, Y., Maia, R. F., Sumedha, S., Shahbazi, M., & Santos, H. A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01638-2 · Cited by 28
Strong, C., Leung, J., Kang, E., Badior, K. E., Robertson, M. K., Pereyra, N., Rowe, E. M., Wietrzny, A., Ma, B., Noronha, Z., et al. (2024) · Blood · doi:10.1182/blood.2024024405 · Cited by 19
Acute interstitial nephritis after messenger RNA-based vaccination
Czerlau, C., Bocchi, F., Saganas, C., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab180 · Cited by 15
Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.030 · Cited by 17
Sen, P., Lilleker, J. B., Agarwal, V., Kardeş, S., Milchert, M., Gheita, T. A., Salim, B., Velikova, T. V., Gracia‐Ramos, A. E., Parodis, I., et al. (2022) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_221_21 · Cited by 20
Németh, D., Vágó, H., Tóthfalusi, L., Ulakcsai, Z., Becker, D. A., Szabo, Z., Rojkovich, B., Merkely, B. P., & Nagy, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960001 · Cited by 17
Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 18
Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination
Wu, V., López, C. A. G., Hines, A., & Barrientos, J. C. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247022 · Cited by 15
Great Expectations of COVID-19 Herd Immunity
Giurgea, L. T., & Morens, D. M. (2022) · mBio · doi:10.1128/mbio.03495-21 · Cited by 16
Mues, K. E., Kirk, B., Patel, D., Gelman, A., Chavers, L. S., Talarico, C. A., Esposito, D. B., Martin, D., Mansi, J. A., Chen, X., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.025 · Cited by 16
Rabaan, A. A., Bakhrebah, M. A., Mutair, A. S. A., Alhumaid, S., Al-Jishi, J. M., AlSihati, J., Albayat, H., Alsheheri, A., Aljeldah, M. M., Garout, M. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10070985 · Cited by 16
Rosati, M., Agarwal, M., Hu, X., Devasundaram, S., Stellas, D., Chowdhury, B., Bear, J., Burns, R., Donohue, D. E., Pessaint, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009701 · Cited by 14
Wang, Q., Nair, M. S., Anang, S., Zhang, S., Nguyen, H., Huang, Y., Liu, L., Ho, D. D., & Sodroski, J. G. (2021) · iScience · doi:10.1016/j.isci.2021.103393 · Cited by 15
“Multiple vaccine approaches employing SARS-CoV-2 spike (S) glycoprotein immunogens have demonstrated significant clinical efficacy (Anderson et al., 2020; AstraZeneca, 2021; Baden et al., 2021; Johnson, 2021; Novavax, 2021; Polack et al., 2020; Voysey et al., 2021; Xia et al., 2021).”
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Ambrosino, D. M., Han, H. H., Hu, B. T., Liang, J. G., Clemens, R. L., Johnson, M., Siber, G. R., & Goldblatt, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab574 · Cited by 16
Immune Responses against SARS-CoV-2—Questions and Experiences
Mangge, H., Kneihsl, M., Schnedl, W. J., Sendlhofer, G., Curcio, F., & Domenis, R. (2021) · Biomedicines · doi:10.3390/biomedicines9101342 · Cited by 16
Fierro, C. A., Sánchez-Crespo, N., Makrinos, D. L., Zhang, W., Sun, Y., Rohilla, P., Girard, B., Adeniji, A., DiPiazza, A. T., & Paris, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1501275 · Cited by 19
Self-citationLong-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Tandler, C., Heitmann, J. S., Michel, T., Marconato, M., Jaeger, S. U., Tegeler, C. M., Denk, M., Richter, M., Oezbek, M. T., Maringer, Y., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.009 · Cited by 16
RNA interference therapeutics for cardiac regeneration
Huntington, J., Pachauri, M., Ali, H., & Giacca, M. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.05.007 · Cited by 18
Wallace, H., & Mount, P. F. (2021) · Internal Medicine Journal · doi:10.1111/imj.15636 · Cited by 15
Mori, Y., Uchida, N., Harada, T., Katayama, Y., Wake, A., Iwasaki, H., Eto, T., Morishige, S., Fujisaki, T., Ito, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26769 · Cited by 14
Lyski, Z. L., Kim, M. S., Lee, D. X., Raué, H.-P., Raghunathan, V. M., Griffin, J., Ryan, D., Brunton, A. E., Curlin, M. E., Slifka, M. K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006633 · Cited by 14
Lan, Z., Yan, J., Yang, Y., Tang, Z., Guo, X., Wu, Z., & Jin, Q. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05216-5 · Cited by 16
Presby, D. M., & Capodilupo, E. R. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00420.2021 · Cited by 15
Lipid-Based Nanocarriers in Renal RNA Therapy
Su, C.-T., See, D. H. W., & Huang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020283 · Cited by 16
Wu, S., Yang, Y., Lian, X., Zhang, F., Hu, C., Tsien, J., Chen, Z., Sun, Y., Vaidya, A., Kim, M., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13154 · Cited by 15
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
Parra-Lucares, A., Toro, L., Weitz-Muñoz, S., & Ramos, C. (2021) · Viruses · doi:10.3390/v13122493 · Cited by 16
COVID-19 vaccination acceptance in the canton of Geneva: a cross-sectional population-based study
Wisniak, A., Baysson, H., Pullen, N., Nehme, M., Pennacchio, F., Zaballa, M.-E., Guessous, I., & Stringhini, S. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30080 · Cited by 17
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15
Sindet‐Pedersen, C., Michalik, F., Strange, J. E., Christensen, D. M., Nouhravesh, N., Gerds, T. A., Andersson, C., Folke, F., Biering‐Sørensen, T., Fosbøl, E. L., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010617 · Cited by 17
Corosolic acid derivative-based lipid nanoparticles for efficient RNA delivery
Liu, Y., Zhang, R., Yang, Y., Liu, X., & Jiang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.073 · Cited by 16
Jennewein, M. F., Schultz, M. D., Beaver, S., Battisti, P., Bakken, J., Hanson, D. J., Akther, J., Zhou, F., Mohamath, R., Singh, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.007 · Cited by 25
Guo, C. M., Chai, X., Baerlike, M., Liu, Y., Wang, Y., Shao, F., Huang, Q., Zhang, W., Cen, S., Dong, Y., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.09.002 · Cited by 17
Sergeeva, O. V., Luo, L., & Guiseppi‐Elie, A. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1499474 · Cited by 23
Major cardiac concerns in therapy and vaccinations for COVID-19
Junapudi, S. S., Junapudi, S., Ega, K., & Chidipi, B. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100102 · Cited by 15
Urdaneta, V., Esposito, D. B., Dharia, P., Moraga, M. S., Anteyi, K., Oduyebo-Omotosho, T., Rossi, M., Burton, P. B. J., Vega, J. M., Dawson, R. S., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae067 · Cited by 18
Cao, X., Manhas, A., Chen, Y. M., Caudal, A., Mondéjar‐Parreño, G., Zhu, W., Liu, W., Kong, X., Zeng, W., Liu, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq0143 · Cited by 22
Lonze, B. E., Spiegler, P. A., Wesson, R., Alachkar, N., Petkova, E., Weldon, E. P., Dieter, R. A., Li, Y., Quinn, M. M., Mattoo, A., et al. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005591 · Cited by 18
Wang, S., Zhang, C., Liang, B., Wang, W., Feng, N., Zhao, Y., Wang, T., Guo, Z., Yan, F., Yang, S., et al. (2022) · Viruses · doi:10.3390/v14061127 · Cited by 16
Chen, M., Venturi, V., & Munier, C. M. L. (2023) · Biology · doi:10.3390/biology12071035 · Cited by 18
Marc, G. P., Álvarez-Paggi, D., & Polack, F. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150135 · Cited by 16
Serious harms of the COVID-19 vaccines: a systematic reviewPreprint
Gøtzsche, P. C., & Demasi, M. (2022) · medRxiv · doi:10.1101/2022.12.06.22283145 · Cited by 19
Figueiredo, J. C., Hirsch, F. R., Kushi, L. H., Nembhard, W. N., Crawford, J. M., Mantis, N. J., Finster, L. J., Merin, N. M., Merchant, A. A., Reckamp, K. L., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac171 · Cited by 15
Christensen, B., Laydon, D. J., Chełkowski, T., Jemielniak, D., Vollmer, M., Bhatt, S., & Krawczyk, K. (2022) · JMIR Infodemiology · doi:10.2196/35121 · Cited by 21
Mateo‐Urdiales, A., Sacco, C., Petrone, D., Bella, A., Riccardo, F., Manso, M. D., Bressi, M., Siddu, A., Brusaferro, S., Palamara, A. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36854 · Cited by 15
Skarzynska, M. B., Matusiak, M., & Skarzynski, P. H. (2022) · Audiology Research · doi:10.3390/audiolres12030025 · Cited by 15
O'Brien, M. P., Forleo-Neto, E., Sarkar, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.14.21258569 · Cited by 16
Impact of Sex and Age on mRNA COVID-19 Vaccine-Related Side Effects in Japan
Mori, M., Yokoyama, A., Shichida, A., Sasuga, K., Maekawa, T., & Moriyama, T. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01309-22 · Cited by 20
Self-limited Polymyalgia Rheumatica-like Syndrome Following mRNA-1273 SARS-CoV-2 Vaccination
Izuka, S., Komai, T., Natsumoto, B., Shoda, H., & Fujio, K. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8829-21 · Cited by 18
Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review
Paul, P., Janjua, E., Al-Subaie, M., Ramadorai, V., Mushannen, B., Vattoth, A. L., Khan, W., Bshesh, K., Nauman, A., Mohammed, I., et al. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2120 · Cited by 16
Glycolipid nanoparticles target the spleen and detarget the liver without charge
Gentry, K., Lian, L., Kim, H., Celik, O., Jones, C., Podilapu, A. R., Shakked, A., Loughrey, D., Zenhausern, R., Jang, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409569122 · Cited by 18
Biologics for Psoriasis During the COVID-19 Pandemic
Zeng, H., Wang, S., Chen, L., & Shen, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.759568 · Cited by 17
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.